Three-Year Follow-up on Safety and Effectiveness of Rituximab Plus Chemotherapy As First-Line Treatment of Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Feng, Jifeng
Wu, Jianqiu
Song, Yongping
Su, Liping
Zhang, Mingzhi
Li, Wei
Hu, Yu
Zhang, Xiaohong
Gao, Yuhuan
Niu, Zuoxing
Feng, Ru
Wang, Wei
Peng, Jiewen
Li, Xiaolin
Ouyang, Xuenong
Wu, Changping
Zhang, Weijing
Zeng, Yun
Xiao, Zhen
Liang, Yingmin
Zhuang, Yongzhi
Wang, Jishi
Sun, Zimin
Bai, Hai
Cui, Tongjian
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5208
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ANALYSIS OF EFFICACY, PROGNOSIS AND SAFETY OF RITUXIMAB IN THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
    Zhuang, Qiang
    Xiang, Lina
    Jin, Ting
    Jin, Zhenlin
    ACTA MEDICA MEDITERRANEA, 2020, 36 (02): : 983 - 988
  • [22] CHOP chemotherapy plus rituximab compared with CHOP alone in diffuse large B-cell lymphoma patients
    Poddubnaya, I
    Osmanov, D
    Babicheva, L
    Falaleeva, N
    ANNALS OF ONCOLOGY, 2005, 16 : 177 - 177
  • [23] Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
    Maakaron, Joseph E.
    Asch, Adam
    Popplewell, Leslie
    Collins, Graham P.
    Flinn, Ian W.
    Ghosh, Nilanjan
    Keane, Colm
    Ku, Matthew
    Mehta, Amitkumar
    Roschewski, Mark
    Hacohen-Kleiman, Gal
    Huo, Yanan
    Zhang, Yi
    Renard, Camille
    Smith, Sonali M.
    Advani, Ranjana
    BLOOD ADVANCES, 2024, 8 (22) : 5864 - 5874
  • [24] A Phase II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma.
    Tsurumi, Hisashi
    Goto, Naoe
    Hara, Takeshi
    Kasahara, Senji
    Kanemura, Nobuhiro
    Kitagawa, Junichi
    Yoshikawa, Takeshi
    Yamada, Toshiki
    Sawada, Michio
    Takahashi, Takeshi
    Takami, Tsuyoshi
    Moriwaki, Hisataka
    BLOOD, 2008, 112 (11) : 1231 - 1231
  • [25] Efficacy Of Rituximab To Chemotherapy In The Treatment Of EBV-Positive Diffuse Large B-Cell Lymphoma
    Beltran, Brady E.
    Chavez, Julio C.
    Castillo, Jorge J.
    BLOOD, 2013, 122 (21)
  • [26] A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
    Morschhauser, Franck
    Feugier, Pierre
    Flinn, Ian W.
    Gasiorowski, Robin
    Greil, Richard
    Illes, Arpad
    Johnson, Nathalie A.
    Larouche, Jean-Francois
    Lugtenburg, Pieternella J.
    Patti, Caterina
    Salles, Gilles Andre
    Trneny, Marek
    de Vos, Sven
    Mir, Farheen
    Samineni, Divya
    Kim, Su Y.
    Jiang, Yanwen
    Punnoose, Elizabeth
    Sinha, Arijit
    Clark, Emma
    Spielewoy, Nathalie
    Humphrey, Kathryn
    Bazeos, Alexandra
    Zelenetz, Andrew D.
    BLOOD, 2021, 137 (05) : 600 - 609
  • [27] Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
    Ren, Yuan-Rong
    Jin, Yong-Dong
    Zhang, Zhi-Hui
    Li, Li
    Wu, Ping
    CHINESE MEDICAL JOURNAL, 2015, 128 (03) : 378 - 383
  • [28] Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
    Arcari, Annalisa
    Chiappella, Annalisa
    Valenti, Vanessa
    Zanlari, Luca
    Tani, Monica
    Marasca, Roberto
    Cabras, Maria Giuseppina
    Spina, Michele
    Santagostino, Alberto
    Ilariucci, Fiorella
    Carli, Giuseppe
    Musto, Pellegrino
    Savini, Paolo
    Marino, Dario
    Ghio, Francesco
    Gentile, Massimo
    Cox, Maria Christina
    Della Seta, Roberta
    Vallisa, Daniele
    BLOOD, 2014, 124 (21)
  • [29] Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
    Ren Yuan-Rong
    Jin Yong-Dong
    Zhang Zhi-Hui
    Li Li
    Wu Ping
    中华医学杂志英文版, 2015, 128 (03) : 378 - 383
  • [30] Rituximab-bendamustine for first-line treatment of older patients with diffuse large B cell lymphoma: a multicenter analysis
    Zeremski, V.
    Kahl, C.
    Mohren, M.
    Jentsch-Ullrich, K.
    Eberhardt, J.
    Fischer, T.
    Schalk, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 45 - 46
12345